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Abstracts 
N0-39. INTRAOCULAR LYMPHOMA DEVELOPED AFTER 
SALVAGE CHEMOTHERAPY FOR RECURRENT PRIMARY CNS 
LYMPHOMA AND PROMISING THERAPY-A CASE REPORT 
Beverly Dan Fu, Xiao-Tang Kong, and Daniela A. Bora; UC Irvine Medical 
Center, Orange, CA 
Intraocular Lymphoma (IOL) is a subset of primary central nervous system 
lymphoma (PCNSL), a rare form of non-Hodgkin's B-cell lymphoma. The 
frequency of IOL has been rising in immunocompetent patients. We report 
the challenges of obtaining a diagnosis and the treatment of a female 
patient who has developed IOL after three cycles of salvage therapy with 
intravenous methotrexate for her recurrent PCNSL 5 years after the initial 
diagnosis of PCNSL. A 68-year-old woman was diagnosed with a large 
B-Cell central nervous system lymphoma in 2005 by brain tumor biopsy. 
She was in remission after 5 cycles of high-dose methotrexate for three 
years. The patient received two additional courses of methotrexate for recur­
rences 3 and 4 years after the initial diagnosis. Four and a half years after the 
PCNSL diagnosis, she developed vitritis and received high dose solumedrol 
with very slight improvement. CSF cytology was negative. A vitrectomy of 
her right eye was performed, and pathology showed CD-20 positive large 
B-cells. Immediately following the diagnosis of IOL, we started her on intra­
venous rituximab and oral temozolomide concomitant with intravitreal 
injection of rituximab. Eventually, the temozolomide was discontinued 
because of hematologic toxicities. The patient had a total of 4 intravenous 
rituximab and 8 intravitreal rituximab treatments in both eyes. Her repeated 
vitreous biopsy showed no malignant cells. Her visual acuity has no further 
deterioration. IOL should be suspected in patients who present with vision 
impairment and have a history of PCNSL. CSF study might be negative in 
most of the patients with isolated IOL or even with PCNSL. Vitreous 
biopsy or vitrectomy with corresponding pathology is still the gold standard 
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in the diagnosis of primary intraocular lymphoma. lntravitreal rituximab 
injection concomitant with systemic rituximab and temozolomide might 
be a promising therapy for IOL. Further study of more cases is warranted. 
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